Literature DB >> 14746066

Freebies for subject 641: a discussion of the ethical prospect of providing drug trial subjects with post-trial access to the drug tested--a Canadian perspective.

L E Hutt1.   

Abstract

"Pharmaceutical Company Incorporated" is developing a new drugs to treat AIDS. The Company is hoping to begin clinical trials soon and has submitted its tiral proposal for consideration by the Research Ethics Board (REB). The proposal includes provision to supply the drug free of charge to trial subjects if the drug is shown to be effective and safe. The members of the REB are split as to whether such an offer is acceptable. Some members of the REB are concerned that the offer is an undue inducement for prospective subjects to participate in the clinical trial.

Entities:  

Keywords:  Biomedical and Behavioral Research

Mesh:

Substances:

Year:  1998        PMID: 14746066

Source DB:  PubMed          Journal:  Health Law J        ISSN: 1192-8336


  4 in total

1.  Access to medications and medical care after participation in HIV clinical trials: a systematic review of trial protocols and informed consent documents.

Authors:  Andrea L Ciaranello; Rochelle P Walensky; Paul E Sax; Yuchiao Chang; Kenneth A Freedberg; Joel S Weissman
Journal:  HIV Clin Trials       Date:  2009 Jan-Feb

2.  Subjects' views of obligations to ensure post-trial access to drugs, care and information: qualitative results from the Experiences of Participants in Clinical Trials (EPIC) study.

Authors:  N Sofaer; C Thiessen; S D Goold; J Ballou; K A Getz; G Koski; R A Krueger; J S Weissman
Journal:  J Med Ethics       Date:  2009-03       Impact factor: 2.903

3.  Reasons Why Post-Trial Access to Trial Drugs Should, or Need not be Ensured to Research Participants: A Systematic Review.

Authors:  Neema Sofaer; Daniel Strech
Journal:  Public Health Ethics       Date:  2011-07-11       Impact factor: 1.940

4.  Reciprocity-based reasons for benefiting research participants: most fail, the most plausible is problematic.

Authors:  Neema Sofaer
Journal:  Bioethics       Date:  2013-12-06       Impact factor: 1.898

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.